Phase II clinical trial - Pédiatrie Tumeurs solides

MK-7902-013
Pédiatrie Tumeurs solides
Essai clinique fermé
Public cible
Enfant
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)
Description de l'essai
The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.
ISABELLE AERTS
Investigateur principal